Otamixaban

Otamixaban
	File:Otamixaban.svg
	File:Otamixaban 3D.png
Systematic (IUPAC) name
	Methyl (2R,3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate
Identifiers
CAS Number	193153-04-7
ATC code	none
PubChem	CID: 5496659
ChemSpider	4593439
UNII	S173RED00L
ChEMBL	CHEMBL46618
Chemical data
Formula	C25H26N4O4
Molecular mass	446.498 g/mol
	SMILES O=C(OC)[C@H](Cc1cc(C(=[N@H])N)ccc1)[C@H](NC(=O)c3ccc(c2cc[n+]([O-])cc2)cc3)C ;
	InChI InChI=1S/C25H26N4O4/c1-16(22(25(31)33-2)15-17-4-3-5-21(14-17)23(26)27)28-24(30)20-8-6-18(7-9-20)19-10-12-29(32)13-11-19/h3-14,16,22H,15H2,1-2H3,(H3,26,27)(H,28,30)/t16-,22-/m1/s1 ; Key:PFGVNLZDWRZPJW-OPAMFIHVSA-N ;
(what is this?) (verify)

Otamixaban (INN) is an experimental injectable anticoagulant direct factor Xa inhibitor,^[1] that was investigated for the treatment for acute coronary syndrome. In 2013, Sanofi announced that it had ended development of the drug candidate after poor performance in a Phase III clinical trial.^[2]^[3]

References

This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it.